Sichuan Biokin Pharmaceutical's innovative drug BL-ARC002 injection has received approval for clinical trials.

15:41 22/03/2026

Bailey Tianheng (688506.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The company's independently developed innovative drug, BL-ARC002 injection, has been approved for clinical trials.

Sichuan Biokin Pharmaceutical (688506.SH) announced that the company has recently received the official approval from the National Medical Products Administration (NMPA) for the issuance of the "Drug Clinical Trial Approval Notice" for its self-developed innovative drug BL-ARC002 injection. The announcement stated that BL-ARC002, with its antibody-mediated precise targeted delivery technology and powerful tumor-killing ability of radioactive isotopes, has stronger target specificity and higher tumor enrichment compared to traditional radioactive isotope-conjugated drugs. It is also expected to demonstrate better resistance to drug resistance.

Guangdong Hongda Holdings Group, the controlling shareholder of Xinjiang Xuefeng Sci-Tech (603227.SH), plans to increase its holdings by 150 million to 300 million yuan.

HaiXin Foods (002702.SZ) controlling shareholder Teng Yongxiong and concerted parties intend to reduce their shareholding by no more than 1%.

One of the controlling shareholders of Guangzhou Devotion Thermal Technology (300335.SZ), Ma Ge, plans to reduce his shareholding by no more than 1%.

Guangdong Hongda Holdings Group, the controlling shareholder of Xinjiang Xuefeng Sci-Tech (603227.SH), plans to increase its holdings by 150 million to 300 million yuan.

HaiXin Foods (002702.SZ) controlling shareholder Teng Yongxiong and concerted parties intend to reduce their shareholding by no more than 1%.

One of the controlling shareholders of Guangzhou Devotion Thermal Technology (300335.SZ), Ma Ge, plans to reduce his shareholding by no more than 1%.